The Board of Directors of Sun Pharmaceutical Industries Ltd has, declared an interim dividend of Rs. 7.50/- per equity share of Re. 1/- each of the Company for the financial year 2022-23.
/PRNewswire/ If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this.
The Board of Directors of Sun Pharmaceutical Industries Limited, at its meeting held today have approved the financial results of the company for the period ended December 31, 2022 - Q3FY23 and 9MFY23.
Sun Pharmaceutical Industries Ltd has acquired three brands viz. Disperzyme®, Disperzyme-CD® and Phlogam® from Aksigen Hospital Care, a Mumbai based research driven healthcare entity with more than two decades of experience in the healthcare field.